Literature DB >> 22551773

A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.

Lauriane Goldwirt1, Florian Lemaitre, Noel Zahr, Robert Farinotti, Christine Fernandez.   

Abstract

A sensitive and accurate liquid chromatography method with mass spectrometry detection using MRM in positive ion mode was developed and validated for the simultaneous quantification of irinotecan (CPT-11) and 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and brain. Camptothecin (CPT) was used as internal standard. A single step protein precipitation was used for plasma sample preparation, and a liquid-liquid extraction was needed for brain sample preparation. The method was validated with respect to selectivity, extraction recovery, linearity, intra- and inter-day precision and accuracy, limit of quantification and stability. Limits of quantification were 5 ng/mL for CPT-11 and SN-38 in plasma samples and 1.25 ng/g in brain. Linear calibration curves were obtained over concentration ranges of 5-5000 ng/mL in plasma and 1.25-1250 ng/g in brain for CPT-11 and SN-38. The intra-day and inter-day variation (relative standard deviation, R.S.D.) found to be less than 15% for both substances in both media. Stability studies showed that plasma carboxylesterase had to be inactivated in order to prevent in vitro conversion of CPT-11 into SN-38. Zinc sulfate (1 M) was used to inactivate the enzyme before sample storage. Brain samples did not require enzyme inactivation. This method was successfully applied to perform brain and plasma pharmacokinetic studies of CPT-11 and SN-38 in mice after intraperitoneal administration.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551773     DOI: 10.1016/j.jpba.2012.04.003

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

Authors:  Ferro Nguyen; Ivan Alferiev; Peng Guan; David T Guerrero; Venkatadri Kolla; Ganesh S Moorthy; Michael Chorny; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2018-03-07       Impact factor: 12.531

2.  Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.

Authors:  Sumit Basu; Min Zeng; Taijun Yin; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-09       Impact factor: 3.205

3.  Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.

Authors:  Lauriane Goldwirt; Kevin Beccaria; Alexandre Carpentier; Ahmed Idbaih; Charlotte Schmitt; Camille Levasseur; Marianne Labussiere; Aline Milane; Robert Farinotti; Christine Fernandez
Journal:  J Neurooncol       Date:  2015-01-13       Impact factor: 4.130

4.  Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.

Authors:  Ferro Nguyen; Peng Guan; David T Guerrero; Ivan S Alferiev; Michael Chorny; Garrett M Brodeur; Venkatadri Kolla; Koumudi Naraparaju; Lauren M Perry; Danielle Soberman; Benjamin B Pressly
Journal:  Cancer Res       Date:  2020-08-24       Impact factor: 12.701

5.  A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting.

Authors:  Yang Liu; Dan Li; Xinhong Guo; Haiwei Xu; Zhi Li; Yanling Zhang; Chuanjun Song; Ruhan Fan; Xing Tang; Zhenzhong Zhang
Journal:  Int J Nanomedicine       Date:  2017-03-22

6.  Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.

Authors:  Wenqian Yang; Zimeng Yang; Jieru Liu; Dan Liu; Yongjun Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-11       Impact factor: 6.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.